research Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system
Enfortumab vedotin can cause skin issues, especially in older males, needing early monitoring.
Search
for
Sort by
Research
660-690 / 1000+ results 
research Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system
Paternal drug exposure can harm fertility, pregnancy outcomes, and offspring health, with specific drugs linked to various reproductive issues.
research 112 Post-Finasteride Syndrome – Outcomes of FDA Database
research Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
In 2024, the FDA approved 27 innovative small-molecule drugs, with many offering significant treatment improvements.
research Simultaneous spectrophotometric determination of finasteride and tadalafil in recently FDA approved Entadfi™ capsules
The methods accurately measure finasteride and tadalafil in Entadfi™ capsules for quality control.
research A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
Pexidartinib often causes liver issues and fatigue, especially in women.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
research Innovations in skin microphysiological systems for nonclinical testing and FDA modernization
New technologies replicate human skin for testing without animals.
research PD29-07 DRUGS ASSOCIATED THE MOST WITH MALE-FACTOR INFERTILITY: ASSESSMENT OF THE 2010-2020 FOOD AND DRUG ADMINISTRATION (FDA) PHARMACOVIGILANCE DATABASE
Finasteride and testosterone are the drugs most linked to male infertility, but many other potential drugs may be under-reported.
research 0557 Possible Contributory and Protective Factors in Medication Associated Obstructive Sleep Apnea (OSA): Results from the US Food and Drug Administration (FDA) Adverse Events Reporting System (FAERS)
Some drugs may increase the risk of obstructive sleep apnea, while others like certain biologics might decrease it.
research 054 Post Finasteride Syndrome: Guess Who-Demographics from FDA Database
Younger people (median age 35) experience more PFS-like symptoms with 1mg finasteride; more research needed.
research A microscopy-based small molecule screen in primary neurons reveals neuroprotective properties of the FDA-approved anti-viral drug Elvitegravir
The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.
research A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System
Avacopan may cause unexpected side effects, so early monitoring is important.
research Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system
Cladribine has known risks and potential new safety concerns, requiring careful monitoring.
research Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database
Ipilimumab can cause various adverse events in elderly patients, especially affecting the gastrointestinal and endocrine systems.
research Sustainable UV approaches supported by greenness and whiteness assessments for estimating a recently FDA-approved combination for managing urologic disorders: Tukey's test
New, eco-friendly methods accurately measure TDF and FNS in a new urologic medication.
research Development of validated methods for the simultaneous quantification of Finasteride and Tadalafil in newly launched FDA-approved therapeutic combination: greenness assessment using AGP, analytical eco-scale, and GAPI tools
The study developed accurate, precise, and environmentally friendly methods to measure Finasteride and Tadalafil in a new FDA-approved combination.
research 0917 Finasteride is Associated with a Higher Odds of Obstructive Sleep Apnea (OSA): Results from the US FDA Adverse Events Reporting System (FAERS)
Finasteride increases risk of sleep apnea and insomnia.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Is finasteride intake associated with penile curvature/peyronie’s disease? Assessment of both the food and drug administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases
research Suicidal behaviors (suicidal ideation, suicide attempt and completed suicide) in patients treated with finasteride for hair loss: Results from the U.S. FDA Adverse Event Reporting System (FAERS) database
research Androgenetic Alopecia: An Update of Treatment Options
Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
research Alopecia Areata: An Updated Review for 2023
Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.
research The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials
The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.
research Expert System for Hair Loss Diagnosis and Treatment
Minoxidil and Propecia are the only FDA-approved hair growth drugs, but concerns about side effects lead people to explore herbal alternatives.
research Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study
Low-dose finasteride may cause lasting sexual dysfunction and suicidal thoughts in young men.
research Nanotechnology-Based Cosmetics for Hair Care
Nanotechnology improves hair care products by enhancing ingredient stability, targeting treatment, and reducing side effects, but more research on its toxicity is needed.
research Bidirectional Barbed Sutures for Wound Closure: Evolution and Applications
Bidirectional barbed sutures are effective and can reduce surgery time, with a low infection rate and potential cost savings despite being more expensive.
research ANDROGENETIC ALOPECIA
Finasteride and minoxidil are effective FDA-approved treatments for androgenetic alopecia.